[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586769":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":26,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":32,"collaborators":11,"id":36,"slug":11,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":11,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":11},{"fullName":5,"class":6},"University of Cologne","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Progression Free Survival",null,"PFS at 1 year",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20],{"label":21,"type":22,"description":23,"interventionNames":24},"Treatment","EXPERIMENTAL","Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET\u002FCT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively.",[25],"Drug: BrECADD",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","BrECADD","Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone",[21],{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Prof. Dr. Peter Borchmann","Prof.","100586769",false,"NCT06919679","Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma","BASTION","Inclusion Criteria:\n\n* Histologically confirmed first diagnosis of cHL\n* Advanced-stage disease: stage IIB with large mediastinal mass and\u002For extranodal lesions or stage III or IV\n* No previous treatment for HL with the exception of steroid prephase\n* Confirmed HIV infection with CD4 counts ≥ 150\u002FμL at registration or \\> 250\u002FμL at any time within 8 months prior to HL diagnosis\n* Continuation of antiretroviral treatment (ART) \u002F Initiation of ART in patients who are ART-naive\n* Age: 18-60 years\n\nExclusion Criteria:\n\n* Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment\n* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma\n* Multi-drug resistant HIV infection or concurrent AIDS-defining conditions\n* Pregnancy or breastfeeding","ALL","18 Years","60 Years",{"count":46,"type":47},35,"ESTIMATED","INTERVENTIONAL",[50],"PHASE2","Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET\u002FCT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.",[53],"Hodgkin Lymphoma (Category)",[55,56,57],"advanced stage","HIV positive","Brentuximab Vedotin","NOT_YET_RECRUITING","2025-04-02",{"date":61,"type":62},"2025-04-09","ACTUAL",{"date":64,"type":47},"2025-08",{"date":66,"type":47},"2030-01",{"name":5,"class":6}]